INO Inovio Pharmaceuticals: Year-over-year earnings per share growth for the last twelve months

Corporate emblem and logo of Inovio (INO)

Inovio Pharmaceuticals (INO) develops DNA-based therapies for cancer and viruses, aiming for stable cash flow through commercialization. The GURU.Markets platform displays the quarterly EPS change, where 42.90 defines the current value of the metric. The company's success depends on regulatory approvals, and the implementation of a direct genetic code delivery platform will accelerate the protection of humanity against new pandemics.

Inovio (INO) - Year-over-year net earnings per share change for the last twelve months from 07/04/2022 to 11/15/2026

Analytical breakdowns for Inovio Pharmaceuticals

- share price and consensus valuation forecast:
Stock Quotes Inovio Pharmaceuticals, Inc.|INO - Analyst Consensus Forecast
- company stock capitalization data:
Market Value Inovio Pharmaceuticals, Inc.|INO - Company Buyout Price
- book capitalization data:
Book Value per Share Inovio|INO - Book Valuation of Business|Market Value to Book Value Ratio inovio.com|INO - Total Business Assets
- debt level and financial liquidity data:
Debt to Equity Inovio Pharmaceuticals|INO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Inovio|INO - Company Debts|Debts to Book Capitalization Inovio Pharmaceuticals, Inc.|INO - Long-Term Debt Volume|Company Short-Term Debt Inovio|Quick Liquidity Indicator inovio.com
- earnings and valuation multiples indicators:
INO - Final Profit|Expected Profit Inovio Pharmaceuticals|INO - Market Cap to Net Income|Forward P/E Multiple Inovio Pharmaceuticals|INO - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Inovio Pharma|INO - Operating profit EBITDA|Earnings per share for the last twelve months Inovio|INO - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months inovio.com|INO - Net earnings per share growth this year|Earnings growth forecast for next year Inovio Pharmaceuticals
- sales and revenue data:
INO - Revenue and Sales Volume|Projected Sales Volume Inovio Pharma|INO - Market Cap to Revenue|Forward P/S Multiple Inovio Pharmaceuticals Inc|INO - Trailing Twelve Months Revenue Growth
Fundamental valuation:Inovio Pharma - INO
Manufactured product of inovio.com

The absence of commercial DNA vaccine sales for Inovio Pharmaceuticals (INO) makes pricing dependent on clinical trial outcomes. Under these conditions, quarterly EPS growth reflects the dynamics of net income per share, accounting for operational R&D expenses. This metric measures capital management efficiency and the cash burn rate. It is critical for investors to distinguish systemic progress from random fluctuations. By analyzing the quarterly EPS change, one can assess the actual resilience of the business.

Competitors of Inovio Pharmaceuticals (INO)

Gilead Sciences Inc (GILD) - Year-over-year earnings per share growth for the last twelve months|Cidara - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months NVAX|Quarterly EPS earnings growth curevac.com|Year-over-year earnings per share growth for the last twelve months Valneva Corp (VALN)|Year-over-year earnings per share growth for the last twelve months VIR (Vir Biotechnology)|Year-over-year earnings per share growth for the last twelve months TPOXX SIGA|EBS - Year-over-year net earnings per share growth for the last 12 months|AVIR: Year-over-year net earnings per share growth for the last 12 months|IVVD (Invivyd Inc) - Year-over-year earnings per share growth for the last 12 months|ENTA: Quarterly EPS earnings growth|HLVX (HilleVax Inc) - Year-over-year earnings per share growth for the last twelve months|KLRS (Kalaris Therapeutics Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months DYAI (Dyadic International)|Year-over-year net earnings per share growth for the last 12 months NNVC (NanoViricides)|TLPH (Talphera, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Cocrystal Pharma Inc COCP|Year-over-year earnings per one share growth for the last 12 months TRAW|Dogwood Therapeutics Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Qualigen Corp|ALVR (AlloVir Bio) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months VBI Vaccines, Inc.|VIRI (virios.com) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months VXRT (Vaxart, Inc.)